Abstracts & Posters
IASP 2020
Beyond the Numbers: A Validations Study of the Pain Tolerability Question
JOA 2020
Efficacy of Tanezumab, a Nerve Growth Factor Antibody, in Japanese Patients With Chronic Low Back Pain: A 56-Week Treatment, Celecoxib-Controlled, Study
EULAR 2020
Efficacy of Subcutaneous Tanezumab for the Treatment of Chronic Low Back Pain: An Analysis of Brief Pain Inventory-Short Form Scores from a Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial
AAN 2020
Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16-Week Efficacy and Safety Results from a Phase 3 Study
NeuPSIG 2019
Assessment of the Efficacy and Safety of Vixotrigine in Participants With Lumbosacral Radiculopathy: Results of a Randomized, Placebo-Controlled Trial
EFIC 2019
Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results From a 56-Week Phase 3 Study With a 24-Week Follow Up Period